A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia

Basit Öğe Kaydı
dc.authorid0000-0002-3385-8359
dc.authorid0000-0003-1237-8281
dc.authorid0000-0001-9636-4113
dc.contributor.authorGemici, Aliihsan
dc.contributor.authorÖzkalemkaş, Fahir
dc.contributor.authorDoğu, Mehmet Hilmi
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorAlacacıoğlu, İnci
dc.contributor.authorGüney, Tekin
dc.contributor.authorİnce, İdris
dc.contributor.authorGedük, Ayfer
dc.contributor.authorAkgün Çağlıyan, Gülsüm
dc.contributor.authorMaral, Senem
dc.contributor.authorSerin, İstemi
dc.contributor.authorGündüz, Eren
dc.contributor.authorKarakuş, Volkan
dc.contributor.authorBeköz, Hüseyin Saffet
dc.contributor.authorEren, Rafet
dc.contributor.authorPınar, İbrahim Ethem
dc.contributor.authorGüneş, Ahmet Kürşad
dc.contributor.authorSargın, Fatma Deniz
dc.contributor.authorSevindik, Ömür Gökmen
dc.date.accessioned2021-08-26T07:13:32Z
dc.date.available2021-08-26T07:13:32Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractVenetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML. Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.
dc.identifier.citationGemici, A., Özkalemkaş, F., Doğu, M. H., Tekinalp, A., Alacacıoğlu, İ., Güney, T. ... Sevindik, Ö. G. (2021). A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia, 21(8), E686-E692. https://dx.doi.org/10.1016/j.clml.2021.04.004
dc.identifier.doi10.1016/j.clml.2021.04.004
dc.identifier.endpageE692
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.issue8
dc.identifier.scopusqualityQ2
dc.identifier.startpageE686
dc.identifier.urihttps://dx.doi.org/10.1016/j.clml.2021.04.004
dc.identifier.urihttps://hdl.handle.net/20.500.12511/7984
dc.identifier.volume21
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherCIG Media Group
dc.relation.ispartofClinical Lymphoma, Myeloma & Leukemiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectBcl2
dc.subjectInhibitor
dc.subjectVenetoclax
dc.subjectAcute Myeloid Leukemia
dc.subjectReal Life
dc.titleA real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Gemici-Aliihsan-2021.pdf
Boyut:
588.32 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu